SCHEMBL849165

SCHEMBL849165

Cc1cc(C(=O)N2CCC(O)CC2)cc(C)c1C=CS(=O)(=O)N1CCC2(CC1)NC(=S)NC2=O

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.35
CRBN Q96SW2 4/20 0.34
USP2 O75604 1/20 0.33
ALDH1A1 P00352 4/20 0.32
KMT2A Q03164 1/20 0.32
HTT P42858 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
POLB P06746 1/20 0.32
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
RECQL P46063 1/20 0.31
HSD11B1 P28845 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
ACACB O00763 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL849164 1.00 CNR2 (0.35) CNR2CRBNUSP2ALDH1A1KMT2A
SCHEMBL18211329 0.91 CRBN (0.44) CNR2CRBNUSP2ALDH1A1KMT2A
SCHEMBL850418 0.88 CRBN (0.37) CNR2CRBNALDH1A1HTTPOLB
SCHEMBL850417 0.88 CRBN (0.37) CNR2CRBNALDH1A1HTTPOLB
SCHEMBL850955 0.85 CRBN (0.35) CRBNALDH1A1HTTPOLBACACB
SCHEMBL850956 0.85 CRBN (0.35) CRBNALDH1A1HTTPOLBACACB
SCHEMBL13064741 0.80 CNR2 (0.41) CNR2USP2ALDH1A1KMT2AHTT
SCHEMBL13064738 0.79 HPGD (0.43) CNR2ALDH1A1KMT2AHPGDPOLB
SCHEMBL849322 0.79 ALDH1A1 (0.38) CNR2USP2ALDH1A1KMT2AHTT
SCHEMBL849321 0.79 ALDH1A1 (0.38) CNR2USP2ALDH1A1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 CNR2 1502/4885CRBN 1932/4885USP2 4813/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 CNR2 1502/4885CRBN 1932/4885USP2 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.